Alligator Bioscience Q2 2025: Progress with HLX22 and Mitazalimab - Redeye

Redeye comments on Alligator Bioscience's second quarter report 2025. There has been positive news about HLX22, which we have reevaluated. Mitazalimab is essentially phase III ready. Management is working to find a partner to fund it. Alligator needs proceeds from TO13 in September to fund the rest of 2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1117406/alligator-bioscience-q2-2025-progress-with-hlx22-and-mitazalimab?utm_source=finwire&utm_medium=RSS